Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association

This summarises current literature on cardiorenal protective effects with SGLT2 inhibitors and GLP-1 receptor agonists in patients with CKD and type 2 diabetes, including potential mechanistic pathways that may drive these benefits; literature on adverse effects is also covered.

Circulation